INNATE PHARMA, NEW PHASE IIa TRIAL WITH IPH 1101 IN CHRONIC MYELOID LEUKEMIA

Marseille, October 22, 2007 - Innate Pharma SA, a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, today announced that it has received approval from the French authorities to start an exploratory Phase II (“Phase IIa”) clinical trial in chronic myeloid leukemia* (“CML”) with IPH 1101, the lead drug candidate of its γδ T cell platform... Innate Pharma's Press Release [PDF]- Communiqué de Presse d'Innate Pharma en français [PDF]-

BioAlliance Pharma, promising in vivo results for a New Entity

Paris, October 22, 2007 - BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, said it will present the first promising in vivo results for its New Entity AMEP, invasive melanoma drug candidate (BA 015 program), at the 15th congress of the European Society of Gene and Cell Therapy, Rotterdam, October 27-30... BioAlliance Pharma's Press Release [PDF] - Communiqué de Presse de BioAlliance Pharma en français (PDF]-

Flamel Technologies, Positive Results of a Phase I Trial

October 18, 2007 - Flamel Technologies (NASDAQ:FLML) announced positive preliminary Phase I data from a trial comparing the safety, tolerability, and long-acting activity of FT-105 versus Lantus , an approved basal insulin. FT-105 is a long-acting recombinant insulin* formulation that uses a new microparticulate adaptation of Flamel's proprietary Medusa® nanoparticle delivery system... Flamel Technologies' Press Release-

bioMérieux’s VIDAS® B·R·A·H·M·S PCT® Assay A First Indication for Sepsis Risk Assessment in the ICU

Oct. 18, 2007 - bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® B·R·A·H·M·S PCT®. The test will be used with critically ill patients on their first day of admission to the Intensive Care Unit (ICU) as an aid to assess their risk for progression to severe sepsis and septic shock... bioMérieux's Press Release -

VIVALIS , FIRST RESEARCH LICENCE IN THE FIELD OF THERAPEUTIC PROTEINS WITH SANOFI-AVENTIS

October 17th, 2007 - Vivalis (Euronext : VLS) announces having granted rights to SANOFI-AVENTIS to evaluate EBx® cell lines, cell substrates derived from avian embryonic stem cells, for the production of monoclonal antibodies... Vivalis' Press Release-

Biospace med, Total Solution to Orthopedic Imaging

Oct. 9, 2007 - Biospace med announced that it has received 510k clearance from the Food and Drug Administration (FDA) to market EOS, a new digital Xray imager in the United States for 2D imaging use. EOS 2D|3D technology is part of a total solution to orthopedic imaging allowing images to be obtained with a low dose of radiation and is capable of long length digital imaging, permitting full-body, uninterrupted digital imaging with a single scan...Biospace med's Press Release -

bioMerieux , Diagnosis and Prognosis of Heart Failure

October 1, 2007. bioMérieux, a global leader in the field of in vitro diagnostics, announces the launch of VIDAS® NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics... bioMérieux's Press Release-

Transgene, therapeutic vaccine candidate TG4040 development program against chronic hepatitis C

Strasbourg, France, October 1, 2007 – Transgene S.A. (Eurolist Paris: FR0005175080) announces today that the first patients have been enrolled in a Phase I trial in Canada of its therapeutic vaccine candidate TG4040 (MVA-HCV). The trial is expected to treat approximately 24 patients that are chronically infected with the Hepatitis C Virus (HCV) and who have relapsed after standard treatment of Ribavirin and Pegylated-Interferon Alpha... Transgene's Press Release [PDF] -
Communiqué de Presse de Transgene [PDF en français] -